PEACE-1
PEACE-1 is the European triplet trial: abiraterone added to hormone therapy and docetaxel improves survival, especially in high-volume disease.
1,173 men; OS HR 0.82 overall, 0.72 in high-volume disease (median 5.1 vs 3.5 years); prostate RT reduced serious urinary events.
- Median 66 vs 52 months with Abiraterone + ADT + docetaxel compared with ADT + docetaxel; about 14 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 25 percent lower chance of the event at any given time (hazard ratio 0.75, likely range 0.59 to 0.95).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: De novo metastatic hormone-sensitive prostate cancer: ADT + docetaxel ± abiraterone ± prostate radiotherapy (2×2 factorial). People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,173 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival, abiraterone vs no abiraterone (with ADT + docetaxel)primary | Abiraterone + ADT + docetaxel | — | 66 months | 0.75 (0.59–0.95) | 0.017 | link |
| ADT + docetaxel | — | 52 months |
Pages like this
not linked directly; found by shared links- TrialLATITUDE
Shares Karim Fizazi, Abiraterone acetate, Prostate cancer.
- TrialCHAARTED (E3805)
Shares Docetaxel, Prostate cancer.
- TrialALSYMPCA
Shares Karim Fizazi, Prostate cancer.
- TrialARASENS
Shares Docetaxel, Prostate cancer.
- TrialPROpel
Shares Abiraterone acetate, Prostate cancer.
- TrialMAGNITUDE
Shares Abiraterone acetate, Prostate cancer.
- PersonRobert A. Gatenby
Shares Abiraterone acetate, Prostate cancer.
- PersonNicholas James
Shares Docetaxel, Abiraterone acetate, Prostate cancer.